{
    "nct_id": "NCT05584111",
    "official_title": "Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects with Advanced Malignancies",
    "inclusion_criteria": "* > 18 years of age\n* Histologic or cytologic confirmation of advanced malignancy that has failed standard of care (SOC) therapy and no further SOC therapy is available or the subject has declined additional SOC therapy\n* Adequate organ and marrow function\n* ECOG PS of 0 or 1\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with any local or systemic antineoplastic therapy within 3 weeks prior to first dose of STC-15\n* Major surgery or radiation within the 3 weeks\n* Immune-related AEs from immunotherapy that required permanent discontinuation\n* Central nervous system (CNS) disease involvement, or prior history of Grade â‰¥3 drug-related CNS toxicity.\n* Active autoimmune disease that has required systemic treatment in the 2 years prior to Screening",
    "miscellaneous_criteria": "Key"
}